Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy
Advanced Materials · 2025-12 · 37 (52)
DOI: 10.1002/adma.202412757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 02.02.2025. Verfasst von Francesca Melle und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Adsorption & Advanced Materials Laboratory (AAML), Department of Chemical Engineering & Biotechnology, University of Cambridge, Philippa Fawcett …. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Pancreatic Neoplasms, Machine Learning, Antineoplastic Agents. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EPSRC, HORIZON EUROPE European Research Council, Engineering and Physical Sciences Research Council.
Abstract (Originalsprache)
Despite improvements in cancer survival rates, metastatic and surgery‐resistant cancers, such as pancreatic cancer, remain challenging, with poor prognoses and limited treatment options. Enhancing drug bioavailability in tumors, while minimizing off‐target effects, is crucial. Metal–organic frameworks (MOFs) have emerged as promising drug delivery vehicles owing to their high loading capacity, biocompatibility, and functional tunability. However, the vast chemical diversity of MOFs complicates the rational design of biocompatible materials. This study employed machine learning and molecular simulations to identify MOFs suitable for encapsulating gemcitabine, paclitaxel, and SN‐38, and identified PCN‐222 as an optimal candidate. Following drug loading, MOF formulations are improved for colloidal stability and biocompatibility. In vitro studies on pancreatic cancer cell lines have shown high biocompatibility, cellular internalization, and delayed drug release. Long‐term stability tests demonstrated a consistent performance over 12 months. In vivo studies in pancreatic tumor‐bearing mice revealed that paclitaxel‐loaded PCN‐222, particularly with a hydrogel for local administration, significantly reduced metastatic spread and tumor growth compared to the free drug. These findings underscore the potential of PCN‐222 as an effective drug delivery system for the treatment of hard‐to‐treat cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Adsorption & Advanced Materials Laboratory (AAML), Department of Chemical Engineering & Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge, CB3 0AS, UK.
- NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisbon, Portugal.
- Comprehensive Health Research Centre (CHRC), NOVA Medical School, Faculdade de Ciências Médicas, NMS, FCM, Universidade NOVA de Lisboa, Lisbon, Portugal.
ORCID-Profile: David Fairen-Jimenez
Förderung
- EPSRC
- HORIZON EUROPE European Research Council
- Engineering and Physical Sciences Research Council
- European Research Council
- FCT - Fundação Ciência e a Tecnologia
Zitieren
APA
Melle, F., Menon, D., Conniot, J., Ostolaza-Paraiso, J., Mercado, S., Oliveira, J., Chen, X., Mendes, B. B., Conde, J., & Fairen-Jimenez, D. (2025). Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy. Advanced Materials, 37(52). https://doi.org/10.1002/adma.202412757
Vancouver
Melle F, Menon D, Conniot J, Ostolaza-Paraiso J, Mercado S, Oliveira J, et al. Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy. Advanced Materials. 2025;37(52). doi:10.1002/adma.202412757
BibTeX
@article{Melle2025,
author = {Melle, Francesca and Menon, Dhruv and Conniot, João and Ostolaza-Paraiso, Jon and Mercado, Sergio and Oliveira, Jhenifer and Chen, Xu and Mendes, Bárbara B and Conde, João and Fairen-Jimenez, David},
title = {Rational Design of Metal–Organic Frameworks for Pancreatic Cancer Therapy: from Machine Learning Screening to In Vivo Efficacy},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {52},
doi = {10.1002/adma.202412757}
}
EUVIMED